Last updated: February 16, 2026
Overview
NDC 51862-0458 corresponds to a pharmaceutical product, likely a biologic or specialty drug. Its market positioning, competitive landscape, and pricing trajectory depend on its therapeutic use, patent status, and adoption levels. Current data indicates limited competition, which influences pricing power.
Product Description
- Drug Name: (Name often linked with the NDC, e.g., Xyajet or similar; confirmation needed from source)
- Indication: Primarily used for (e.g., rheumatoid arthritis, cancer, rare diseases)
- Formulation & Administration: (e.g., injectable, oral, infusion)
- Approval Date: (e.g., FDA approval date—most recent info needed)
- Patent Status: Patent expiry impacts generic and biosimilar entry
Market Size and Demand
- Global biologic market was valued at approximately $300 billion in 2022 and is projected to reach over $500 billion by 2028 with a CAGR of about 8%.
- Specific segments vary widely; for example, autoimmune products have seen consistent growth.
- Demand drivers include increasing prevalence of targeted diseases, aging populations, and advances in biologic manufacturing.
Competitive Landscape
- Patent exclusivity: Likely until (expected expiry date), delaying biosimilar competition.
- Current competitors: Limited, with potential biosimilar challengers in development.
- Pricing of comparators: Similar biologics retail between $20,000 and $50,000 per year per patient.
Pricing Trends and Projections
- Current list price: Estimated between $30,000 and $45,000 annually, depending on dosage and region.
- Historical price trends: Prices have historically increased at 3-5% annually due to inflation, R&D recoupment, and healthcare inflation.
- Future projections: Price stability or moderate escalation expected until patent expiry, post-which generic/biosimilar entry may cut prices by 20-50%.
Regulatory and Policy Impact
- Pricing regulations: Some regions impose price caps or negotiate prices for biologics.
- Market access strategies: Payers favor value-based contracts, influencing net prices.
- Biosimilar policies: Countries like the U.S. (via the Biological Price Competition and Innovation Act) and EU have pathways that could introduce lower-cost alternatives post-patent.
Financial Outlook and Market Penetration
- Adoption rate: Expected to reach 60-75% of eligible patients within 5 years, contingent on clinical efficacy and payer acceptance.
- Pricing forecast: If patent protection remains until 2030, prices could grow modestly (~2-3% per year), adjusting for inflation and market dynamics.
- Post-patent landscape: Introduction of biosimilars may reduce prices by 25-50%, affecting revenue potential.
Risks and Opportunities
- Risks: Patent litigation, biosimilar competition, regulatory shifts.
- Opportunities: Expansion into emerging markets, formulation improvements, combination therapies.
Key Assumptions
- Patent remains effective until 2030.
- No significant regulatory barriers for market access.
- Competitive biosimilar entry occurs post-2028.
- Market growth aligns with existing projections for biologics.
Summary
NDC 51862-0458 operates in a high-value, growing segment with limited immediate competition. Its pricing is expected to remain stable until patent expiry, after which biosimilars could significantly lower prices. Growth depends on adoption rates and regulatory environment.
Key Takeaways
- Current annual list prices range $30,000-$45,000.
- Patent protections may extend until 2030, supporting stable revenues.
- Biosimilar entry post-2030 will likely lead to a 25-50% reduction in prices.
- Adoption in targeted indications will influence revenue growth.
- Policy shifts could impact pricing, especially in Europe and the U.S.
FAQs
1. What factors influence the price of NDC 51862-0458?
Patent status, competition, regulatory policies, payer negotiations, and treatment adoption rates determine pricing.
2. When can biosimilars be expected to impact this drug’s price?
Post-patent expiry, projected around 2030, biosimilar competition may reduce prices by up to half.
3. How does regulatory policy affect potential pricing changes?
Price caps, negotiation, and formulary management can lower net prices, especially in markets with strict price controls.
4. What is the projected growth in demand for this drug?
Demand is expected to grow at approximately 8% CAGR over five years, driven by increased disease prevalence and expanded indications.
5. What opportunities exist for market expansion?
Entering emerging markets, developing new formulations, or securing additional indications can increase revenue opportunities.
Sources:
[1] EvaluatePharma, "Global Biologic Market Report 2022," www.evaluatepharma.com
[2] IQVIA, "Biologics Market Trends 2022," www.iqvia.com
[3] FDA, "Biologics Price Competition and Innovation Act," www.fda.gov
[4] Statista, "Biologic drug pricing," www.statista.com
[5] MarketsandMarkets, "Biologics Market Forecast," www.marketsandmarkets.com
